Overview

The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome

Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
multi-center, double-blind, randomized, placebo-controlled study of the safety and efficacy.
Phase:
Phase 3
Details
Lead Sponsor:
AIM ImmunoTech Inc.
Hemispherx Biopharma
Treatments:
Poly I-C
poly(I).poly(c12,U)